Autoimmune diseases in dogs are a group of conditions in which the immune system mistakenly attacks its own tissues. They can affect the skin, joints, haematopoietic system or gastrointestinal tract. One of the most common intestinal problems is inflammatory bowel disease (IBD), which leads to chronic diarrhoea, weight loss and a reduced quality of life for the dog.
chronic diarrhoea and vomiting,
weight loss despite normal appetite,
recurrent inflammation of the skin or mucous membranes,
weakness, apathy, decline in physical condition,
in some cases, pain and fever.
Current treatment is mainly based on immunosuppressive pharmacotherapy (corticosteroids, cyclosporine, azathioprine), elimination diets, and antibiotics in cases of infection. These therapies can control symptoms, but are often associated with side effects and do not always lead to complete remission.
PRP supports the healing of mucous membranes and reduces local inflammation. It can be used as a supportive therapy in autoimmune skin diseases and chronic inflammation of the gastrointestinal tract.
MSCs exhibit strong immunomodulatory properties. They can ‘reset’ an overly active immune response and support the regeneration of damaged intestinal mucosa. In clinical trials, the use of MSCs in dogs with IBD led to a reduction in symptoms and improved histopathological results.
👉Check out how mesenchymal stem cells work
In diseases where chronic inflammation plays a dominant role, blocking the interleukin-1 pathway helps to reduce the severity of symptoms and improve the patient's quality of life.
👉 Learn more about IL-1 pain therapy and treatment
Stage 1 – mild symptoms of IBD and autoimmune diseases: PRP and elimination diet as support.
Stage 2 – moderate and chronic cases: MSC for immune system modulation and tissue regeneration.
Stage 3 – severe, treatment-resistant diseases: IL-1 and therapies combined with classic pharmacotherapy.
Autoimmune diseases and IBD in dogs are conditions that require an individual approach. Standard treatment controls symptoms, but biological and regenerative therapies – MSC, PRP and IL-1 – are playing an increasingly important role. These therapies address the root cause of the problem by modulating the immune system and supporting tissue regeneration.
No – the disease is chronic, but modern therapies can significantly improve quality of life and put the dog into long-term remission.
Yes – autologous material is used, which minimises the risk of adverse reactions.
It may support mucosal healing and reduce local inflammation, but it is most commonly used as a supportive treatment.
In severe cases that are resistant to standard treatment, especially those with a predominant inflammatory process.
